- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02320318
12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) (IRIS-05)
A 12-week Double-blind, Randomised, Placebo-controlled, Parallel Group Phase III Study, Followed by a 4-week Randomised Withdrawal Period to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study evaluates the efficacy and safety of ibodutant 10 mg, given once daily for 12 weeks in comparison with placebo in female IBS-D patients. Randomisation to ibodutant and placebo will be 1:1. Efficacy is evaluated in terms of weekly response for abdominal pain intensity and stool consistency over 12 weeks of treatment in at least 50% of the weeks of treatment.
The clinical phase of the study comprises up to 2 weeks of screening for patient's eligibility, a 2-week run-in period (treatment-free) for IBS severity assessment, a 12-week double-blind treatment period, a 4-week randomised withdrawal (RW) period and a 2-week safety follow-up, resulting in a maximum 22-week overall duration of the study for each patient.
Patients report their IBS-related symptoms daily in a telephone-based electronic diary from run-in until end of treatment.
Study Type
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Busan, Korea, Republic of, 602739
-
Daegu, Korea, Republic of, 705718
-
Gangwon-do, Korea, Republic of, 200704
-
Gyeonggi-do, Korea, Republic of, 463712
-
Gyeonggi-do, Korea, Republic of, 471701
-
Seoul, Korea, Republic of, 110744
-
Seoul, Korea, Republic of, 138736
-
Seoul, Korea, Republic of, 137701
-
-
-
-
-
Singapore, Singapore, 529889
-
Singapore, Singapore, 308433
-
Singapore, Singapore, 258500
-
-
-
-
-
Kaohsiung, Taiwan, 83301
-
Kaohsiung, Taiwan, 807
-
Taichung, Taiwan, 40201
-
Tainan, Taiwan, 704
-
Taipei, Taiwan, 104
-
Taipei City, Taiwan, 11217
-
Taipei City, Taiwan, 10002
-
Taoyuan, Taiwan, 333
-
Yunlin, Taiwan, 640
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Female patients aged 18 years or older.
- Belonging to the Asian race and specifically to the Chinese, Indian and Korean ethnicity.
Clinical diagnosis of IBS-D according to the following symptoms, based on Rome III modular questionnaire criteria:
Recurrent abdominal pain or discomfort for at least 3 days per month in the last 3 months associated with at least 2 of the following characteristics:
- improvement with defecation
- onset associated with a change in the frequency of stool
- onset associated with a change in form (appearance) of stool.
- Symptom-onset at least 6 months prior to diagnosis.
- Loose or watery stools at least 25% of the time in the last 3 months AND hard or lumpy stools less than 25% of the time in the last 3 months.
- Additional criterion: More than 3 bowel movements per day at least 25% of the time in the last 3 months.
- For patients older than 50 years OR patients with a positive family history of colorectal cancer: Normal results from colonoscopy/flexible sigmoidoscopy performed within the last 5 years.
- For patients aged 65 years or older: Absence of ischaemic colitis, microscopy colitis or any other organic gastrointestinal disease as evidenced by the results of a colonoscopy/flexible sigmoidoscopy with biopsy performed within 6 months.
- For women of childbearing potential: Use of a highly effective contraceptive method with a failure rate <1% per year throughout the entire study period.
- Physical examination without clinically relevant abnormalities during screening.
- No clinically relevant abnormalities in 12-Lead ECG or in laboratory findings.
- Mentally competent, able to give written informed consent, and compliant to undergo all visits and procedures.
- Unrestricted access to a touch-tone telephone.
- Willingness to refrain from using loperamide within 3 days prior to run-in visit and during the run-in period.
Additional criteria at randomisation:
During both weeks of the run-in period:
- A weekly average of worst abdominal pain in the past 24 hours with a score of ≥3.0 on a 0 to 10 point scale.
- At least one bowel movement on each day.
- A weekly average of at least 3 bowel movements per day.
- At least one stool with a consistency of Type 6 or Type 7 according to the Bristol Stool Scale (BSS) on at least 2 days per week.
- Less than 2 bowel movements with a consistency of Type 1 or Type 2 according to the BSS per week.
- Adequate compliance with the e-diary recording procedure defined as at least 11 of 14 days (≥75%) of the nominal daily data entry.
Exclusion Criteria:
- Male gender.
- Diagnosis of IBS with a subtype of constipation, mixed IBS, or un-subtyped IBS.
- Colonic or major abdominal surgery, any other major abdominal surgery or elective major surgery planned or expected during the study.
- History of organic GI abnormalities, inflammatory bowel diseases, complicated diverticulosis, ischaemic colitis, microscopic colitis.
- History of pancreatitis, active biliary duct disease, cholecystitis or symptomatic gallbladder stone disease in the previous 6 months.
- History of gluten enteropathy or lactose intolerance.
- Current or previous diagnosis of neoplasia.
- History of endometriosis.
- History of positive tests for ova or parasites, or clostridium difficile toxin or occult blood in the stool in the previous 6 months.
- History of human immunodeficiency virus infection.
- History of major cardiovascular events in the previous 6 months.
- Uncontrolled hypertension, insulin-dependent diabetes mellitus or abnormal thyroid function.
- Major psychiatric or neurological disorders or unstable medical condition which may compromise the efficacy and safety assessments.
- Evidence of clinically significant hepatic disease, severe renal insufficiency or anemia.
- Relevant changes in dietary habits, lifestyle, or exercise regimen in the previous 2 months.
- Use of prohibited concomitant medication within the previous month such as antibiotics, antimuscarinic drugs, drugs enhancing GI motility and analgesics.
- Pregnancy or breastfeeding.
- Inability to understand or collaborate throughout the study.
- Participation in other clinical studies in the previous 4 weeks or concomitant enrollment in a clinical study.
- Any condition that would compromise the well-being of the patient.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ibodutant 10 mg
Oral tablet once daily for 12 weeks of treatment.
At week 13, patients in the ibodutant 10 mg arm will be re-randomised in a 1:1 ratio to either ibodutant 10 mg or placebo for additional 4 weeks of treatment.
|
Oral tablet, once daily.
Other Names:
|
Placebo Comparator: Placebo
Oral tablet once daily for 12 weeks of treatment.
At week 13, patients in the placebo arm will be mock-re-randomised (switch in blinded conditions) to ibodutant 10 mg for additional 4 weeks of treatment.
|
Oral tablet (identical in appearance and weight to ibodutant tablet), once daily.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Weekly response for abdominal pain intensity AND stool consistency over 12 weeks of treatment in at least 50% of the weeks of treatment (6 out of 12 weeks).
Time Frame: 12-week
|
The patient will be considered a weekly responder if she meets both of the following criteria in the same week:
|
12-week
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Weekly response for abdominal pain intensity over 12 weeks of treatment in at least 50% of the weeks of treatment (6 out of 12 weeks).
Time Frame: 12-week
|
The patient will be considered a weekly abdominal pain responder if she meets the following criterion:
|
12-week
|
Weekly response for stool consistency over 12 weeks of treatment in at least 50% of the weeks of treatment (6 out of 12 weeks).
Time Frame: 12-week
|
The patient will be considered a weekly stool consistency responder is she meets the following criterion:
|
12-week
|
Weekly Response for relief of overall IBS signs and symptoms over 12 weeks of treatment in at least 50% of the weeks of treatment (6 out of 12 weeks).
Time Frame: 12-week
|
The patient will be considered a weekly responder if she has an IBS degree-of-relief equal to "completely relieved/improved" or "considerably relieved/improved".
|
12-week
|
Evaluation of rebound effects
Time Frame: 12-week
|
Comparison between average abdominal pain intensity and stool consistency during the 4-week RW treatment period and baseline in patients who are re-randomised to placebo after being treated with ibodutant.
|
12-week
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Jan F Tack, Prof., Department of Gastroenterology, University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NAK-08
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Irritable Bowel Syndrome With Diarrhea
-
ProgenaBiomeRecruitingIrritable Bowel Syndrome | Irritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome With Constipation | Irritable Bowel Syndrome Characterized by Constipation | Irritable Bowel Syndrome Mixed | Irritable Bowel Syndrome Without Diarrhea | Irritable Bowel | Irritable Bowel Syndrome Aggravated and other conditionsUnited States
-
Federal Stare Budgetary Scientific Institution,...I.M. Sechenov First Moscow State Medical University; RML INVEST, Torkhovsky...CompletedIrritable Bowel Syndrome | Irritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome With Constipation | Irritable Bowel Syndrome MixedRussian Federation
-
Istanbul Medipol University HospitalTepecik Training and Research Hospital; Bozyaka Training and Research Hospital and other collaboratorsRecruitingIrritable Bowel Syndrome | Irritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome With Constipation | Irritable Bowel Syndrome MixedTurkey
-
University of California, Los AngelesCompletedIrritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome With Mixed Bowel HabitsUnited States
-
Thomayer University HospitalCharles University, Czech RepublicActive, not recruitingIrritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome MixedCzechia
-
CinPhloro Pharma, LLCRecruitingIrritable Bowel Syndrome With DiarrheaUnited States
-
Sahlgrenska University Hospital, SwedenBeneo-Institute; Atmo Biosciences Pty LtdRecruitingIrritable Bowel Syndrome With DiarrheaSweden
-
Bahria UniversityCompletedIrritable Bowel Syndrome With DiarrheaPakistan
-
Vedic Lifesciences Pvt. Ltd.CompletedIrritable Bowel Syndrome With DiarrheaIndia
-
I.M. Sechenov First Moscow State Medical UniversityActive, not recruitingIrritable Bowel Syndrome With DiarrheaRussian Federation
Clinical Trials on Ibodutant 10 mg
-
Menarini GroupTerminatedIrritable Bowel Syndrome With DiarrheaGermany, Sweden, United States, United Kingdom, Hungary, Poland, Latvia, Slovakia, Czech Republic
-
Menarini GroupCompletedIrritable Bowel Syndrome With DiarrheaFrance, Italy, Spain, United States, Russian Federation, Germany, Bulgaria, Poland, United Kingdom, Romania, Czech Republic
-
Menarini GroupCompletedIrritable Bowel SyndromeGermany, Denmark, Latvia, Russian Federation, Ukraine, United Kingdom
-
Merck Sharp & Dohme LLCCompleted
-
PfizerCompleted
-
Idorsia Pharmaceuticals Ltd.Completed
-
Vedic Lifesciences Pvt. Ltd.Not yet recruitingUpper Respiratory Tract InfectionsIndia
-
Ferring PharmaceuticalsCompletedChronic Idiopathic ConstipationUnited States, Belgium, Canada, Czech Republic, Hungary, Poland, Slovakia, South Africa, Sweden, United Kingdom
-
Organon and CoCompletedHypercholesterolemia | Heterozygous Familial Hypercholesterolemia
-
Insmed IncorporatedCompletedNon-Cystic Fibrosis BronchiectasisUnited States, Spain, Korea, Republic of, Australia, Denmark, United Kingdom, Italy, Belgium, Singapore, Bulgaria, Germany, Netherlands, New Zealand, Poland